Protagonist Therapeutics, Inc. (PTGX:NASDAQ) closed at $132.04 on November 6, 2026, down 2.38% on the day. The stock trades 17.9% below its 52-week high of $160.81 and 72.2% above its 52-week low of $76.70. Over the past year, it gained 66.0%. Protagonist Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 6, 2025, PTGX closed higher on 134 days (53%). Its best day was June 9, 2026 (+8.00%) and its worst was October 16, 2026 (-5.71%). It never moved 10% or more in a single session. It opened at least 5% above the previous day's high 1 time.
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its product candidates include PTG-100, which has first-in-class potential as an oral, a4b7 integrin-specific antagonist peptide for the treatment of inflammatory bowel disease (IBD); PTG-200, a gastrointestinal-restricted peptide product candidate for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic peptide for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California.
Find more stocks like PTGX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.